LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and Austin, today announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses..

加利福尼亚州森林湖——（商业新闻短讯）——STAAR Surgical Company（纳斯达克股票代码：STAA），EVO系列植入式Collamer®镜片（EVO ICL）的领先开发商、制造商和销售商™) 针对近视、散光和老视，以及在西雅图、芝加哥和奥斯汀设有诊所的顶级眼科集团SharpeVision今天宣布了一项战略协议，为寻求隐形眼镜和眼镜视觉自由的患者提供EVO ICL镜片作为首选。。

STAAR Surgical and SharpeVision will collaborate on marketing and education activities to elevate awareness of EVO ICL and significantly increase availability of the lenses to all qualified patients in SharpeVision clinics. STAAR Surgical will also provide additional practice development and clinical support.

STAAR Surgical和SharpeVision将合作开展营销和教育活动，以提高对EVO ICL的认识，并显着提高SharpeVision诊所所有合格患者的镜片可用性。STAAR Surgical还将提供额外的实践开发和临床支持。

The initial stage of the collaboration includes a target purchase amount of 1,000 ICL units annually, which represents approximately 25% of the group’s refractive procedure volume..

合作的初始阶段包括每年1000个ICL单位的目标购买量，约占集团屈光手术量的25%。。

“We are pleased to announce SharpeVision as a new partner under our U.S. Highway 93 go-to-market program initiated in October 2023. Dr. Sharpe is a leading refractive surgeon known for his LASIK clinics who sees the advantage of EVO ICL over laser-based vision correction for his patients and practice alike,” said Tom Frinzi, President and CEO of STAAR Surgical.

“我们很高兴宣布SharpeVision成为我们于2023年10月启动的美国93号公路上市计划的新合作伙伴。Sharpe博士是一位领先的屈光外科医生，以他的LASIK诊所而闻名，他认为EVO ICL比基于激光的视力矫正对他的患者和实践都具有优势，”STAAR Surgical总裁兼首席执行官Tom Frinzi说。

“Our collaboration will further increase awareness of the patient and practice benefits of EVO ICL, which provides exceptional vision day and night and does not cause dry eye syndrome.”1,2,3.

“我们的合作将进一步提高患者对EVO ICL的认识和实践益处，EVO ICL日夜提供卓越的视力，不会引起干眼症。”1,2,3。

The EVO ICL lens can permanently correct vision without removing corneal tissue and, if desired, is removable by a doctor for added peace of mind. The lens gives the patient flexibility for the future, while also helping to eliminate the hassles of glasses and contact lenses now.

EVO ICL镜片可以在不去除角膜组织的情况下永久矫正视力，如果需要，可以由医生移除，以增加心灵的平静。这种镜片为患者提供了未来的灵活性，同时也有助于消除眼镜和隐形眼镜的麻烦。

“As surgeons like me get more time and experience with any technology, our level of comfort and proficiency grows,” shared Matthew Sharpe, MD, founder and surgeon, SharpeVision. “Given the outstanding outcomes, EVO ICL is now my first recommendation for patients seeking refractive vision correction.

SharpeVision创始人兼外科医生MatthewSharpe博士分享道：“随着像我这样的外科医生在任何技术方面获得更多的时间和经验，我们的舒适度和熟练程度都会提高。”。“鉴于这些出色的结果，EVO ICL现在是我对寻求屈光矫正的患者的第一个建议。

The EVO procedure solves many of the limitations we see in LASIK and PRK laser vision correction surgery including postoperative ocular surface dryness and corneal weakening/ectasia. I have implanted the EVO ICL lenses in more than 600 eyes over the past two years including those of my own son. My son still talks about the freedom of life without glasses or contact lenses and the superb quality of his new vision.”.

EVO手术解决了我们在LASIK和PRK激光视力矫正手术中看到的许多局限性，包括术后眼表干燥和角膜减弱/扩张。在过去的两年里，我已经将EVO ICL镜片植入了600多只眼睛，包括我儿子的眼睛。我儿子仍然在谈论不戴眼镜或隐形眼镜的生活自由以及他新视力的卓越品质。”。

Warren Foust, Chief Operating Officer of STAAR Surgical stated, “EVO ICL has demonstrated proven clinical benefits for patients in the U.S. with refractive error -3.0 diopters and above. As U.S. surgeons continue to move down the diopter curve, we believe that for patients -6.0 diopters and above, EVO ICL will increasingly become their preferred choice.

STAAR Surgical首席运营官沃伦·福斯特（Warren Foust）表示：“EVO ICL已证明对美国屈光不正（屈光不正3.0屈光度及以上）的患者具有临床益处。随着美国外科医生继续沿着屈光度曲线向下移动，我们相信对于屈光度6.0屈光度及以上的患者，EVO ICL将越来越成为他们的首选。

We are proud to partner with SharpeVision as they make EVO ICL available to more patients.”.

我们很荣幸与SharpeVision合作，因为他们使EVO ICL可用于更多患者。”。

For more information about EVO Implantable Collamer® Lenses, please visit https://evoicl.com.

有关EVO植入式Collamer®镜片的更多信息，请访问https://evoicl.com.

References

参考文献

EVO/EVO+ ICL DFU and PIB.

EVO/EVO+ICL DFU和PIB。

Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117–125.

Martinez-Plazs E，Lopez-Miguel A，Lopez-De-La Rosa A等。EVO+Visian有晶状体植入胶原透镜对视觉表现和视觉与生活质量的影响，Am J Ophthalmol 2021；226:117-125。

Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

Naves，J。Carracedo，G。Cacho-Babillo，I。二腺苷核苷酸测量作为LASIK和ICL手术后患者的干眼症评分。2012年在美国白内障和屈光手术学会（ASCRS）上发表。

About STAAR Surgical

关于STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision.

STAAR专门从事眼科手术已有40多年的历史，它设计、开发、制造和销售用于眼睛的植入式镜片。这些镜片旨在为患者提供视觉自由，减少或消除对眼镜或隐形眼镜的依赖。所有这些镜片都是可折叠的，这使得外科医生可以通过一个小切口将它们插入。

STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,500,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

用于屈光手术的斯塔尔晶状体被称为植入式Collamer®晶状体或“ICL”，其中包括EVO ICL™ 产品线。迄今为止，已售出250多万个ICL，STAAR在75多个国家销售这些镜片。欲了解更多有关ICL的信息，请访问：EVOICL.com。该公司总部位于加利福尼亚州森林湖，在加利福尼亚州的Aliso Viejo、加利福尼亚州的蒙罗维亚和瑞士的Nidau经营制造和包装设施。

For more information, please visit the Company’s website at www.staar.com..

欲了解更多信息，请访问公司网站www.staar.com。。

About SharpeVision

关于SharpeVision

SharpeVision is a premier ophthalmology group that brings the best refractive and cataract surgeons, technologies and correction procedures to our patients, all for the best price. SharpeVision clinics offer EVO ICL, LASIK, PRK and cataract procedures that are designed to address the three vision milestones of adult life – ocular maturity (prescription stability and the opportunity to correct nearsightedness, farsightedness and astigmatism); dysfunctional lens syndrome (presbyopia ages 45-60); and cataract development (ages 60+).

SharpeVision是一家一流的眼科集团，为我们的患者带来最好的屈光和白内障外科医生、技术和矫正程序，所有这些都是以最好的价格提供的。SharpeVision诊所提供EVO ICL、LASIK、PRK和白内障手术，旨在解决成人生活中的三个视力里程碑-眼部成熟（处方稳定性以及矫正近视、远视和散光的机会）；晶状体功能障碍综合征（45-60岁的老视）；和白内障发展（60岁以上）。

SharpeVision’s goal is to restore the ability to see clearly which is an essential part of being the best version of yourself. SharpeVision currently operates clinics in Austin, TX, Chicago, IL and Seattle-Bellevue, WA. To learn more, please visit www.sharpe-vision.com..

SharpeVision的目标是恢复清晰的视觉能力，这是成为最佳自我的重要组成部分。SharpeVision目前在德克萨斯州奥斯汀、伊利诺伊州芝加哥和华盛顿州西雅图贝尔维尤设有诊所。欲了解更多信息，请访问www.sharpe-vision.com。。

Important Safety Information for EVO ICL

EVO ICL的重要安全信息

The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before.

EVO Visian ICL镜片旨在矫正/减少-3.0 D至-20.0 D的近视，并治疗1.0 D至4.0 D的散光。如果您的近视在这些范围内，EVO Visian ICL手术可能会改善您的远视力，而无需眼镜或隐形眼镜。因为EVO Visian ICL可以校正远视，所以它并不能消除对阅读眼镜的需求，即使您以前从未戴过，您也可能会在某些时候需要它。

Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.

由于植入EVO Visian ICL是一种外科手术，因此在考虑EVO Visian ICL手术之前，您应该进行全面的眼科检查，并与您的眼科护理专业人员讨论EVO Visian ICL手术，特别是潜在的益处，风险和并发症。你应该讨论手术后愈合所需的时间。

Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation, 3) you have moderate to severe glaucoma, 4) your vision is not stable; or 5) if you are pregnant or nursing..

并发症虽然很少见，但可能包括需要额外的外科手术，炎症，角膜后表面细胞的丢失，眼压升高和白内障。如果您的医生确定1）您的眼睛形状不合适，2）您在植入时不符合您年龄的最低内皮细胞密度，3）您患有中度至重度青光眼，4）您的视力不稳定；或5）如果你怀孕或哺乳。。

For additional information with potential benefits, risks and complications please visit evoicl.com.

有关潜在益处、风险和并发症的更多信息，请访问evoicl.com。

Safe Harbor

安全港

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond.

所有非历史事实陈述的陈述均为前瞻性陈述，包括关于以下任何一项的陈述：2024年及以后的任何财务预测（包括销售）、计划、战略和管理目标，或实现此类计划的前景、销售预期、收入、利润率、费用或收益，以及基于上述任何假设的任何报表，包括与即将到来的季度、2024财年及以后的财务业绩有关的报表。

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.

可能导致实际结果与此类前瞻性声明所示结果产生重大差异的重要因素包括与全球经济状况相关的风险和不确定性，以及公司截至12月30日年度报表10-K中规定的因素，2022年，在“风险因素”标题下，该标题已向美国证券交易委员会备案，并可在公司网站“投资者信息”部分的“SEC备案”标题下找到。我们不打算或有义务因新信息或事件而更新或修订任何财务预测或前瞻性声明。

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on dem.

这些声明基于截至本新闻稿发布之日的预期和假设，并受到众多风险和不确定性的影响，这可能导致实际结果与前瞻性声明中描述的结果存在重大差异。风险和不确定性包括：全球经济状况；新型冠状病毒肺炎的影响；监管机构批准或拒绝现有、新的或改进的产品，或在批准之前或之后要求采取额外行动，或采取执法行动的自由裁量权；国际贸易争端和对dem的实质依赖。

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts..

我们打算将我们的网站用作披露重大非公开信息的手段，并遵守FD法规规定的披露义务。此类披露将包含在我们网站的“投资者关系”部分。因此，投资者除了关注我们的新闻稿、SEC文件、公开电话会议和网络广播外，还应该监控我们网站的这些部分。。